US Stock Market Closed

Dashboard

Mirati Therapeutics, Inc. (MRTX)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity

S

Analyst Opinion

B

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.

CEO

Charles M. Baum

Employees

111

Industry

Oncology Biopharmaceuticals

Sector

Healthcare

Headquarters

San Diego

Exchange

NASDAQ

Summary Stats

Market Cap

5.54B

Revenue

11.8M

Net Income

-738M

EPS

-$13.37

Price-to-Earnings

-7.2

Price-to-Book

4.91

Debt-to-Equity

0.15

News

Analyst Ratings

Price targets projected by 14 analysts

High

$300.00

Average

$235.57

Low

$176.00

Ratings calculated by 15 analysts

Buy

10

Hold

4

Sell

1

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Above by $0.39

Actual

-$3.09 +11.2%

Consensus

-3.48

Report Date

Year Ago

-1.55

Year Ago Change %

Down 99%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites